title: [Improvement of short-term prognosis in patients with refractory heart failure].
abstract: BACKGROUND
  Prognosis of patients with severe heart failure is poor, despite improved results in medical therapy. Heart transplantation is the only treatment possible in end-stage heart failure. The aim of this study was to evaluate the variation in prognosis over the past six years in the patients admitted to Intensive Care Unit for heart failure in spite of optimal oral therapy. STUDY POPULATION AND METHOD: Between January 1990 and December 1995, 133 patients with heart failure were admitted to the Intensive Care Unit, despite the fact that they were on optimal oral therapy. All patients were in New York Heart Association (NYHA) functional class III to IV and required intravenous administration of sympathomimetic amines, in addition to standard heart failure treatment procedures. Cumulative survival at six months of patients observed between 1990-1992 (group A) was compared with the survival rate of patients observed from 1993 to 1995 (group B).
  
  
  RESULTS
  Clinical and haemodynamic parameters were similar in groups A and B, but ACE-inhibitors were used more frequently in group B (75 vs 31% respectively, p < 0.05). During the follow-up period, heart transplantation was indicated in a similar percentage of patients (A 53% vs B 58%). However, mortality on the waiting list (58% group A vs 21% group B; p < 0.05) and the percentage of patients who underwent heart transplantation (41% group A vs 78% group B; p < 0.05) differed. Moreover, all patients in group A and 50% of group B were operated on as "status one" patients. The total six-month mortality rate decreased from 69% before 1992 to 48% thereafter (p < 0.05).
  
  
  CONCLUSIONS
  The short-term prognosis of patients with refractory heart failure improved over time. In the latter period, ACE-inhibitors were used more frequently and the number of heart transplantations was greater. Nevertheless, our results do not allow us to identify the causes of the improved survival rate.
authors.affiliation: Cattedra di Cardiologia, Università degli Studi di Padova.
authors.forename: G M
authors.initials: GM
authors.lastname: Boffa
authors.forename: S
authors.initials: S
authors.lastname: Cannas
authors.forename: L
authors.initials: L
authors.lastname: Cacciavillani
authors.forename: A
authors.initials: A
authors.lastname: Marzari
authors.forename: G
authors.initials: G
authors.lastname: Grassi
authors.forename: B
authors.initials: B
authors.lastname: Bauce
authors.forename: U
authors.initials: U
authors.lastname: Livi
authors.forename: F
authors.initials: F
authors.lastname: Maddalena
mesh_terms: D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D001243:Assisted Circulation; D002316:Cardiotonic Agents / Q000627:therapeutic use; D003325:Coronary Care Units; D003627:Data Interpretation, Statistical; D004280:Dobutamine / Q000627:therapeutic use; D004298:Dopamine / Q000627:therapeutic use; D004837:Epinephrine / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000188:drug therapy / Q000401:mortality* / Q000503:physiopathology; D016027:Heart Transplantation; D006439:Hemodynamics; D006440:Hemofiltration; D006801:Humans; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000627:therapeutic use; D011379:Prognosis; D015996:Survival Rate; D013566:Sympathomimetics / Q000627:therapeutic use; D013997:Time Factors; D012122:Ventilators, Mechanical
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents; D013566:Sympathomimetics; D004280:Dobutamine; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine